The regulation of lipid metabolism was observed with olverembatinib but not with other TKIs clinically used for SDH-deficient GIST treatment, which could explain the superior clinical efficacy of olverembatinib. The gene discussed is SDHB; the disease is gastrointestinal stromal tumor.